register

News & Trends - Pharmaceuticals

Novartis and Gates Foundation collaborate on gene therapy

Health Industry Hub | February 19, 2021 |
[Total: 1    Average: 5/5]

Pharma News: Novartis entered into a grant agreement with the Bill & Melinda Gates Foundation to provide funding support for the discovery and development of a single-administration gene therapy to cure sickle cell disease (SCD).

The project brings together Novartis drug discovery and gene therapy expertise with the Gates Foundation’s charitable objectives to expand access to healthcare in low-resource settings in an effort to address this potentially life-threatening genetic disease.

“Existing gene therapy approaches to sickle cell disease are difficult to deliver at scale and there are obstacles to reaching the vast majority of those affected by this debilitating disease,” said Jay Bradner, a haematologist and President of the Novartis Institutes for BioMedical Research (NIBR). “This is a challenge that calls for collective action, and we are thrilled to have the support of the Bill & Melinda Gates Foundation in addressing this global unmet medical need.”

SCD is a hereditary blood disease that affects millions around the world, with over 300,000 born with the condition annually.

While the genetic cause of SCD has been known for decades, it’s only recently that the medical world has gained the tools to potentially fix the errant gene that causes the disease. Current clinical-stage gene-based therapies require extracting cells from a patient, altering those cells in a laboratory, and then reintroducing them to the patient through a complex procedure akin to a bone marrow transplant. The lab and manufacturing facilities and hospital infrastructure for such procedures often do not exist in the areas where SCD is most prevalent, excluding the vast majority of those with the disease from these life-changing gene therapies.

“Gene therapies might help end the threat of diseases like sickle cell, but only if we can make them far more affordable and practical for low-resource settings,” said Trevor Mundel, President of Global Health at the Gates Foundation. “What’s exciting about this project is that it brings ambitious science to bear on that challenge. It’s about treating the needs of people in lower-income countries as a driver of scientific and medical progress, not an afterthought. It also holds the promise of applying lessons learned to help develop potentially curative options for other debilitating diseases affecting low-income populations, such as HIV.”

Novartis envisions developing an accessible in vivo gene therapy for SCD that could potentially be administered once, directly to the patient, without the need to modify the cells in a lab. This would have the advantage of mitigating the need for long or repeated hospital stays or specialized lab infrastructure. To facilitate the research, the Gates Foundation has agreed to provide funding support for a research team within NIBR wholly dedicated to developing an approach to delivering this potential treatment. Novartis will provide in-kind support and access to its suite of technologies and resources.

In addition to research funding, the Gates Foundation lends its long history and experience in global health to this collaboration. As part of the early drug design strategy, Novartis will prioritise addressing access and distribution hurdles posed by limited healthcare infrastructure in low- and middle-income countries and the funding agreement includes specific provisions to support global access to any resulting innovations.

“Novartis is proud to lead this effort to find an accessible genetic therapy for sickle cell disease, with support from the Bill & Melinda Gates Foundation,” said Lutz Hegemann, Group Head of Corporate Affairs & Global Health for Novartis. “In keeping with our purpose, we firmly believe we can use science and innovation to reimagine the way SCD is treated for patients around the world.”

The agreement builds on the Novartis commitment to improve the lives of patients with sickle cell disease through the development of new treatments, including monoclonal antibody Adakveo (crizanlizumab), strategic partnerships with government and non-government organisations, and support for such interventions as newborn screenings and the distribution of existing drugs.


About the author

About the author

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam luctus finibus scelerisque. Nunc bibendum ipsum sed augue fringilla fringilla. Nullam at consectetur leo. Praesent viverra rutrum porta. Quisque vitae mi vel purus vulputate tincidunt. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Suspendisse et mi quis nisi rhoncus feugiat at ac tellus. Sed aliquam sodales nulla ac auctor. Sed pretium lobortis purus accumsan ullamcorper. Phasellus sodales vel odio in lobortis. Duis maximus sagittis bibendum. Interdum et malesuada fames ac ante ipsum primis in faucibus. Nunc dictum tincidunt ipsum in vestibulum. Donec ut sem consectetur, aliquam quam vitae, pharetra orci. Nam egestas non velit eu rhoncus. Duis congue neque non lacus tincidunt porta. Vestibulum ultricies pulvinar sem, molestie congue dui aliquet non.
  • Ut imperdiet leo id lorem fermentum consectetur.
  • Ut vitae orci et dui varius tincidunt.
  • Ut id magna non libero vestibulum pharetra ac faucibus nulla.
Aliquam erat volutpat. Vestibulum vitae varius diam. Nulla eget congue ante. Nunc ullamcorper sagittis augue vel dictum. Mauris finibus nibh ut pulvinar auctor. Vestibulum ut faucibus nisi. Orci varius natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Quisque porta tortor ac justo malesuada elementum. Nulla tellus ante, cursus nec ex sit amet, suscipit bibendum arcu. Duis posuere orci dui, et mollis enim dictum at. Sed ullamcorper, sapien ut vulputate viverra, sem purus porttitor tellus, nec mattis mauris ligula sed risus. Nulla sagittis id ipsum eu mattis. Link to full profile

News & Trends - Medical Technology

MedTech News - Johnson & Johnson breaking down barriers to gender equality

Johnson & Johnson breaking down barriers to gender equality

Health Industry Hub | February 26, 2021 |

MedTech News: The Johnson & Johnson Family of Companies in Australia is pleased to announce that the company has been […]

More


Human Resources

Human Resource Management - National gender pay gap drops to 13.4%

National gender pay gap drops to 13.4%

Health Industry Hub | February 26, 2021 |

Human Resources: The Workplace Gender Equality Agency announced today that that national gender pay gap has dropped to 13.4%, a decline […]

More


News & Trends - Medical Technology

MedTech News - Philips one of first MedTechs to become carbon neutral

Philips, one of first MedTechs to become carbon neutral

Health Industry Hub | February 26, 2021 |

MedTech News: Philips Healthcare Australia, a global leader in health technology, has successfully met all the targets set out in […]

More


Social Responsibility

Social Responsibility and Community Engagement - The race to win the 2021 Medicines Australia, Kosi Pharma-Cup

The race to win the 2021 Medicines Australia Kosi Pharma-Cup

Health Industry Hub | February 26, 2021 |

The countdown is on for Rare Cancer Australia’s Kosi Challenge and the battle to win the Pharma-Cup sponsored by Medicines […]

More